BioMarin Pharmaceutical Inc, a leading, global rare disease biotechnology company, has appointed Indian American executive Arpit Davé as Executive Vice President, Chief Digital and Information Officer, a new position.
In this role, Davé will be responsible for reimagining and executing BioMarin’s enterprise technology strategy, data science and digital transformation to help create value for patients, employees and shareholders, San Rafael, California-based company announced.
Davé is a proven leader who brings to the role more than 20 years of experience in information technology and artificial intelligence (AI) in the biopharmaceutical industry, according to the release. He has a strong track record of driving patient-focused organizations to deliver measurable business growth and profitability.
Davé joins BioMarin from Amgen, Inc., where he has served as a technology executive for the past seven and a half years. In his most recent roles, he was responsible for the teams driving digital transformation through artificial intelligence and digital technology and innovation, focused on evolving the company to be competitive in the rapidly changing era of AI.
READ: Walmart names Superhuman’s Shishir Mehrotra to company board (January 13, 2026)
Prior to Amgen, he held leadership roles at Bristol Myers Squibb and Merck, with a focus on CIO leadership, data science and research and development.
Davé holds an M.S. in Industrial Engineering from the University of Texas and a B.S. in Mechanical Engineering from Sardar Patel University in Gujarat, India.
“Arpit is a visionary thinker and talented leader who brings to this role a deep understanding of the biopharmaceutical industry and a track record of using technology and AI to deliver for patients and the business,” said Alexander Hardy, President and Chief Executive Officer.
“He will be responsible for building a strategic vision and roadmap, deploying technologies that will further differentiate and improve BioMarin’s business operations across the company from research and development to our manufacturing and commercial organizations, now and in the future.”
“I have long admired BioMarin’s dedication to people living with rare diseases and I am excited to work as part of this team to create undeniable value for patients, employees and shareholders,” said Davé.
“I am honored to join BioMarin at this pivotal moment where the convergence of biology, data and AI offers unprecedented potential; my focus will be on empowering our world-class teams and driving innovation to translate these capabilities into faster insights and the accelerated delivery of life-changing therapies to the patients who depend on us.”
Founded in 1997, BioMarin has a proven track record of innovation, with eight commercial therapies and a strong clinical and preclinical pipeline, according to the release.